Insmed: A Deep-Dive Value Investing Research Report

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it enlarging an existing slice of the pie, or creating an entirely new market?5/10

  A

  The conclusion first: Insmed's ceiling is neither "enlarging a mature slice of the pie" nor "creating an entirely new market" out of nothing; it sits between the two. In two respiratory rare diseases that were long neglected and had almost no approved targeted drugs, it does the work of "converting diagnosed-but-untreated existing patients into treated patients." This gives it real but bounded room to grow, far from "unlimited imagination."

  First, look at bronchiectasis (non-cystic fibrosis, NCFB), the larger ceiling. This is BRINSUPRI's main battlefield and the core of the company's value imagination. The key fact is that before BRINSUPRI, this disease had been recorded in the medical literature for more than two hundred years without any approved targeted therapy, and BRINSUPRI became the first and only FDA-approved NCFB therapy in August 2025. So strictly speaking, rather than seizing an existing prescription pie (targeted drugs simply did not exist in that pie before), it is turning a field that "could only be treated symptomatically, with no disease-modifying therapy" into a market with an available drug for the first time, which is closer to "creating a market."

  But the ceiling is not as high as the marketing narrative claims. The market sizes given in the report are about 500,000 diagnosed in the U.S., about 600,000 across the five major European countries, and about 150,000 in Japan, with an honest reminder that these are estimates based on external research and internal analysis. Third-party data are somewhat more conservative: DelveInsight estimates the U.S. NCFB diagnosed population at about 390,000 in 2024, exceeding 470,000 by 2034. Whichever measure you take, this is a "hundreds-of-thousands-scale" specialty disease, not a tens-of-millions-scale mass market like hypertension or diabetes. What truly determines the ceiling is penetration and pricing: Insmed set BRINSUPRI's annual price (before discounts) at about $88,000, which means that even penetrating just a low-double-digit percentage of the diagnosed population can support billion-dollar-scale single-product revenue. That is exactly why management issued guidance of at least $1 billion in BRINSUPRI revenue for 2026. In other words, the height of the ceiling comes mainly from "high price × gradual penetration," rather than an explosion in the patient base itself.

  Now look at ARIKAYCE, whose nature is completely different: a classic case of "enlarging and defending a small existing slice of the pie." The refractory MAC lung disease population it targets is narrower. The report discloses about 95,000 to 115,000 diagnosed patients in the U.S., of whom only 12,000 to 17,000 are refractory. This is a mature, narrow-indication product in its eighth year on the market, growing only about 5.7% year over year this quarter (ARIKAYCE revenue of $98.1 million in Q1 2026). Its real chance to lift the ceiling lies in expanding the label from "refractory" to "all MAC lung disease patients," and in March 2026 ENCORE Phase 3b read out positive results (6-month culture-conversion rate 87.8% vs 57.0%), and the company plans to submit an sNDA in the second half of 2026. This is a genuine "enlarging the pie," but still confined within the MAC rare-disease frame.

  Overall judgment: this company's market ceiling is "moderate, clear, and quantifiable," not "too high to measure." Its growth narrative rests on the real logic of "a first-in-class drug awakening a dormant rare-disease market," which is a positive; but the limited patient base and heavy dependence on payers being willing to pay for high-priced innovative drugs mean it cannot enjoy the compounding imagination of platform or consumer companies, where "penetration and per-capita spending both rise without limit." Against Baillie Gifford's preferred standard of "enlarging an entirely new pie," it is a partial match rather than a high-scoring one.

  Jun 11, 2026
• QOver the next five years, can its revenue at least double? Is growth driven mainly by volume, price, or new business?7/10

  A

  The conclusion first: for Insmed, doubling revenue over the next five years is "almost already happening" rather than an open question of "whether it can"; and the growth engine is highly concentrated in new-business ramp (the penetration of BRINSUPRI, a newly launched single product), not price increases and not the organic growth of older products. The difficulty is not the doubling itself, but whether it can keep growing fast after doubling to support the current valuation.

  First, let's pin down the "doubling." Total product revenue was $606.4 million in 2025; Q1 2026 single-quarter total revenue already reached $306.0 million, nearly half of full-year 2025 in just one quarter. Management guides 2026 BRINSUPRI to at least $1 billion and ARIKAYCE to $450–470 million, which together are about $1.45–1.47 billion. In other words, in 2026 alone total revenue is already close to double that of 2025. So "doubling in five years" is clearly a conservative bar that the current trajectory will most likely clear within one or two years, and a reasonable reference point five years out is "more than two to three times 2025." This is a real advantage of the company relative to many growth stocks: the growth is not a promise on paper but already shows up in the quarterly financials.

  What drives the growth? The answer is very clear: volume, and mainly the volume of the new product.

  The first driver is BRINSUPRI's patient ramp. It only received U.S. approval in August 2025, and Q1 2026 single-quarter revenue already reached $207.9 million, up about 44% quarter over quarter versus the fourth quarter of 2024. This is a classic "first-in-class early-launch, rapidly converting diagnosed existing patients into treated patients" ramp curve, plus the international additions from successive EU approval in November 2025 and U.K. approval in February 2026. In essence it is driven by "new-patient count × persistence," not by unit-price increases.

  The second driver is ARIKAYCE's label expansion, which too is a "volume" story rather than "price." It is already a mature product (Q1 up only about 5.7% year over year, the U.S. base even down slightly, with the increment coming mainly from international), and it is hard to grow much on the existing label alone; but ENCORE Phase 3b is positive, with a planned sNDA submission in the second half of 2026 to expand the indication from "refractory" to "all MAC lung disease", and if approved it would expand the treatable population from the 12,000–17,000 refractory patients to the overall MAC group of 95,000–115,000 — a volume-growth logic that enlarges the indication population several-fold.

  Price increases ("price") are barely a growth source. Innovative-drug pricing power is constrained by commercial insurance, government payers, and rebate negotiations, and BRINSUPRI is already set at a high $88,000/year. As the treated population expands in the future, payer scrutiny of net price and budget impact will only tighten, leaving little room to drive revenue through price increases. The report's judgment is consistent: the real moat "does not lie in raising prices every year."

  So the honest conclusion has two layers: on "can it double in five years," the answer is most likely yes, even overshooting, with clear and already-delivering momentum — real growth. But by Baillie Gifford's higher standard of "finding great growth stocks that 5x in ten years," the key variable is not this doubling, but whether BRINSUPRI's persistence (refill) rate and net price can be sustained after penetration reaches a high level. These two points are still being built and not yet proven by multiple years of data, which is exactly the core reason for judging it "high-quality growth but high-expectation."

  Jun 11, 2026
• QFive years out, what will take over as the next growth engine? Does this "second curve" exist today?4/10

  A

  The conclusion first: five years out, the real "second curve" candidate is TPIP (treprostinil palmitil inhalation powder) plus the earlier-stage immune-inflammatory pipeline, but it must be said honestly that this second curve today exists only in the clinical pipeline and is not yet proven; it is currently "optional upside (optionality)," not an established growth engine. Treating it as a certain successor is one of the optimistic assumptions implied by the current share price.

  First, sort out which is the "first curve" and which is the "second curve." Today's real money-making engines are BRINSUPRI (Q1 2026 single-quarter $207.9 million, still ramping fast) and ARIKAYCE. But strictly speaking, BRINSUPRI is still in the rising segment of the first curve; within five years it is itself the main growth source, so "being handed off" hardly applies. So the question of "who takes over in five years" really points to: once BRINSUPRI's penetration curve flattens and ARIKAYCE's label-expansion dividend is fully realized, what sustains the growth? The report's answer, and what its valuation bets on, is that TPIP can "turn from an option into a genuine third growth pillar."

  The TPIP line exists today, but its quality is unknown. According to the report, its key raw material depends on a single Taiwan-based supplier (supply-chain concentration is a real risk), and it targets pulmonary-arterial-hypertension-related indications. Its status is "in development, key Phase III not yet read out, not yet approved, contributing no revenue." The report places its uncertainty in the most prominent position: in the counterarguments it explicitly writes that "TPIP delivering at least one indication" is one of the necessary conditions for the valuation to hold, and it lists "a key TPIP Phase III failure, shattering the market's hope for a third growth curve" as a core signal that would materially lower the valuation and even trigger reassessment. In other words, even the report itself does not treat TPIP as an accomplished fact, but as a high-variance variable that is "icing on the cake if it holds, and a chunk out of the valuation if it fails." This is exactly the honest attitude: TPIP is a genuinely existing option, but the option's intrinsic value today is close to "at the mercy of chance."

  Beyond TPIP, the second tier also includes earlier-stage projects such as INS1148, and a pipeline arrayed across the three therapeutic areas of "immune-inflammatory, neurological, and other rare diseases." But the earlier the stage, the farther from revenue and the higher the failure rate, and the weaker the realistic contribution to "taking over within five years." They mainly support the narrative that "this is not a pure two-product story," rather than being definite numbers that can go into a five-year revenue model.

  Here we should add a Baillie Gifford–style implicit premise: the real second curve is best if it "grows naturally out of core capabilities, rather than luckily betting on a new molecule." On this point Insmed has half confidence and half concern. The confidence lies in having twice run the full "molecule–clinical–regulatory–specialty commercialization" chain for respiratory rare diseases (ARIKAYCE and BRINSUPRI); this organizational capability of "developing and commercializing high-unmet-need respiratory/rare-disease drugs" is itself a reusable engine — being able to keep pushing pipeline into products is itself a "self-regenerating" second-curve generation mechanism. The concern is that the success or failure of a single candidate (such as TPIP) is still a discrete, binary clinical bet; organizational capability can raise the odds but cannot guarantee that any specific pipeline will succeed.

  So the honest conclusion: the second curve "exists today" — represented by TPIP, plus the reusable R&D-commercialization platform — which is superior to many biotechs that have only a single product and no follow-on. But it "is not yet proven today," with value almost entirely in discounting the future and highly dependent on clinical readouts. Against Baillie Gifford's standard of "whether the second curve is already clearly visible today," Insmed's answer is "there are candidates, there is a platform, but no established new engine yet" — a state that is moderate-to-positive but must never be inflated into certainty.

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?5/10

  A

  The conclusion first: Insmed's core competitive advantage is the combination of "first-in-class/first-to-launch label + patent and regulatory barriers + specialty commercialization capability," rather than brand, network effects, or cost advantage. This moat genuinely exists, but it belongs to the kind "maintained by continuous execution and the regulatory clock," not a self-widening commercial flywheel. My judgment for the next three to five years is: slightly widening in the short term, and dependent in the medium term on when competitors arrive — there are both widening catalysts and clear narrowing risks, direction undetermined.

  First, what the moat is made of. The hardest piece is first-to-launch exclusivity + regulatory barriers. BRINSUPRI is the first and only FDA-approved therapy for non-cystic fibrosis bronchiectasis, and also the first approved DPP1 inhibitor; in refractory MAC lung disease, the company states it is not aware of any other approved dedicated inhaled therapy in North America, Europe, or Japan, and it is recommended by multiple guidelines from ATS/ERS/ESCMID/IDSA. "Highly exclusive at the label level + inclusion in treatment guidelines" is the most solid part of this river. Next are switching cost and channel: once chronic-disease patients are stable on therapy and physicians have formed prescribing habits, there is real switching inertia; specialty pharmacy/distribution, payer coverage, and academic promotion themselves form entry barriers. The report's ratings of the various moat types are also down-to-earth — brand moderate-to-weak, cost advantage weak, network effect none, patent/regulatory barrier strong — an un-inflated self-assessment.

  Why say it slightly widens in the short term. Two catalysts: first, BRINSUPRI has moved from a "clinical story" to a rapidly ramping commercial asset (Q1 2026 up about +44% quarter over quarter), and every additional patient stable on therapy thickens switching cost and channel stickiness; second, ARIKAYCE's ENCORE Phase 3b read out positive (6-month culture conversion 87.8% vs 57.0%), removing a major regulatory overhang and opening room to expand the indication to the entire MAC group — enlarging the "moat area" of a narrow moat.

  Why say the medium-term narrowing risk is clear and the direction undetermined. The most direct threat is that mechanism-based competition has already arrived: Boehringer Ingelheim's verducatib (BI 1291583) is also a DPP1/CatC inhibitor that has advanced to the Phase III AIRTIVITY study in bronchiectasis, planning to randomize about 1,200 patients, with the primary endpoint being the annualized rate of exacerbations, and its Phase II AIRLEAF has already shown a dose-dependent reduction in exacerbation risk. This shows BRINSUPRI's "island advantage" has a shelf life: once a second drug against the same target is approved, exclusivity in bronchiectasis will be broken, and both pricing power and share will come under pressure. On patents, the point should be stated clearly rather than rounded up optimistically: the report says BRINSUPRI's main patents run to 2035–2040, but public patent databases show its core composition-of-matter patent expires around January 2035, and the generic/challenge window may open earlier, so "to 2040" is on the optimistic side, and the truly reliable exclusivity floor is closer to the 2035 line (ARIKAYCE's U.S. patents are expected to provide coverage at least through 2035). This means the moat's "remaining duration" is a bit over ten years, not unlimited.

  One more key judgment from a Baillie Gifford perspective: this moat is essentially "a regulator-granted time-limited monopoly + execution-delivered channel stickiness", rather than the structural, self-reinforcing-over-time moats of Coca-Cola or Moody's. It will not automatically widen just because the company grows larger — quite the opposite: the more successful it is and the larger the population, the stricter payer scrutiny of real-world efficacy and budget impact becomes, and the stronger the economic incentive for follow-on competition. The report's judgment that "the moat slightly widens in the short term and is undetermined in the medium term," and its 3/5 strength rating, I think both hold up.

  So the honest three-to-five-year answer: the moat is currently enough to support a high-speed ramp, and ENCORE gave it one chance to widen; but whether it can keep widening depends almost entirely on when follow-on players like verducatib arrive, and on how many patients BRINSUPRI can "lock" into stable therapy before competition appears — this is a moat racing against the regulatory clock and the clinical clock, rather than a river that has already self-reinforced and can be left worry-free.

  Jun 11, 2026
• QIf its core business is disrupted, does it have the genes to reinvent itself? How does it treat mistakes and bad news?5/10

  A

  The conclusion first: Insmed has a degree of "self-reinvention genes," but its reinvention capability is of the "pipeline regeneration" type, rather than the "business-model transformation" type. That is, if one core product is disrupted (clinical failure or suppression by a competitor), it has the ability to launch the next drug via its R&D engine, but it cannot switch to a completely different business the way a platform company can. As for its attitude toward mistakes and bad news, from public disclosure management is relatively candid and does not shy away from risk, which is a positive; but "honestly acknowledging risk" and "having already proven it can turn around from a major setback" are two different things, and the latter has not yet been tested.

  First, the implicit premise of "self-reinvention genes." What Baillie Gifford really wants to ask is: when the core business you live on is disrupted, does this company have the underlying ability to "tear it down, start over, and forge a new life"?

  Insmed's positive evidence is that its R&D-commercialization engine is indeed reusable. It has twice pushed a "high-unmet-need respiratory/rare-disease drug" from molecule to launch and run the commercialization through — ARIKAYCE received FDA accelerated approval in 2018, and BRINSUPRI became the first approved NCFB therapy and the first DPP1 inhibitor in 2025. This capability, paired with the intensity of still investing $209.5 million in R&D in Q1 2026 and a pipeline reserve across the three areas of respiratory/immune-inflammatory/neurological, means that even if a single product runs into trouble, it still has the organizational muscle to "forge the next drug." This is a reinvention gene in the "pipeline regeneration" sense, stronger than biotechs that have only one product and no follow-on.

  But two limitations must be stated clearly. First, this reinvention is "change the drug, not the model." Insmed will always be a company that "develops and sells innovative drugs"; it cannot, upon a comprehensive failure in its core therapeutic area, pivot to diagnostics, devices, or services — its fate is bound to the high-variance matter of "continuously having new molecules succeed," and every clinical bet is discrete and binary; organizational capability can raise the odds but cannot guarantee any specific pipeline will succeed. Second, the scenario that truly tests "reinvention from disruption" (such as BRINSUPRI being severely suppressed by a follow-on same-target drug like verducatib, or a TPIP Phase III failure causing the third curve to fall through) has not actually happened to date, so the reinvention capability is more a "reasonable inference based on two past successes" than a "fact validated by adversity."

  Now the attitude toward mistakes and bad news, where the public evidence is relatively positive. The report notes that the company does not shy away from key risks in its 10-K and proxy materials — explicitly disclosing ARIKAYCE's accelerated-approval confirmatory-trial obligation, high customer concentration (in Q1 2026 the four largest customers accounted for 38%, 22%, 16%, and 14% of gross product revenue respectively), single-source supply-chain dependence, long-term losses, and ongoing financing needs. There are also binding governance arrangements: per the report, in 2025 shareholder say-on-pay support for the compensation plan was about 97%, the company disclosed no related-party transactions, and internal controls were deemed effective by management and Ernst & Young at the end of 2025. In presenting bad news it also does not deliberately gloss over — for example, on the point that the Q1 2026 gross margin is temporarily lifted by inventory expensed before launch and should not be mechanically annualized, the report's stance is a factual caution rather than a cover-up. These all point to a management style "willing to put the ugly words up front."

  Still, keep a measure of caution: to date Insmed has not experienced a truly major product failure or recall-level crisis, so "how it treats mistakes" currently shows up mainly in "the candor of its risk disclosure" rather than a "combat record of crisis handling." For a long-loss-making company sustained by capital-market blood transfusions, candor is relatively easy in a tailwind (products approved one after another, share price elevated); the real touchstone is whether, when the headwind comes, it still refrains from whitewashing and does not delay bad news to protect the share price — this remains to be seen.

  Overall judgment: self-reinvention genes — yes, but of the "R&D regeneration" rather than "model transformation" type, and untested by adversity; attitude toward mistakes and bad news — candid at the disclosure level with governance constraints, a credible positive, but lacking a real crisis-combat sample. This is consistent with the report's assessment of management as "basically credible, but not a perfect score."

  Jun 11, 2026
• QDoes management (especially the founder) have long-term vision and interests deeply tied to the company? Is it willing to sacrifice current profit for five to ten years out?4/10

  A

  The conclusion first: Insmed's management has ample long-term vision and is clearly willing to sacrifice current profit for five to ten years out — this hardly needs doubting (the company is by design investing at a continuous loss for the future); but "interests deeply tied to the company" can only be rated moderate, not a perfect score: the CEO has a long tenure and high ownership requirements, but the binding mechanism is mainly compensation incentives rather than founder-style enormous personal ownership, and the price management pays for growth includes continuous heavy dilution that is very unfriendly to existing shareholders. There is no "founder" concept here — Insmed is not a founder-led company.

  First, let's be clear on "long-term vision" and "willingness to sacrifice current profit," where these two points are strengths. Per the report, CEO William H. Lewis has served since 2012 and also as chairman since 2018, giving strong tactical continuity. More importantly, "is it willing to sacrifice the present for the long term" — the company has answered with more than a decade of hard cash: per the report its 2025 GAAP net loss was as high as $1.2768 billion, and in Q1 2026 it still posted a net loss of $163.6 million and R&D investment of $209.5 million. A company that, with products already ramping and able to cut R&D to flatter its financials, instead keeps pouring enormous resources into the pipeline — that itself is the strongest evidence of "sacrificing current profit for five to ten years out." On the trait Baillie Gifford prizes most, "daring to burn cash for the long term and not being held hostage by quarterly earnings," Insmed is a high-scoring match — but one caveat: this "daring to burn cash" is an inherent property of the innovative-drug business model, not entirely a virtue unique to management, since almost everyone in the industry does the same.

  Now "interests alignment," where an honest discount must be applied. First, this is not a founder company; Lewis is a long-tenured professional-manager CEO, not a founder holding enormous personal equity. Per the report, as of the 2026 record date his beneficial ownership was about 1.648 million shares, and management and directors together about 4.427 million shares, only about 2.1% of total shares — this absolute binding ratio is not high, far from the founder-style alignment of "betting one's fortune and life on the company." Second, the company reinforces alignment through institutional ownership requirements: per the report, after the 2025 update the CEO is required to hold stock equal to 600% of annual salary and other executives 300%, and both were satisfied as of the record date; this is a positive governance arrangement, but in essence it is "binding required by rules" rather than "spontaneous heavy-conviction belief."

  The most critical negative is the cost of capital allocation to existing shareholders — the dilution paid for growth is very heavy. The weighted-average share count at the end of Q1 2026 was about 215.5 million shares, while per the report period-end shares rose from about 118.7 million at the end of 2021 to about 214.3 million at the end of 2025 and about 216.5 million by the end of March 2026 — nearly doubling in four years. This means a large part of the money the company uses to "sacrifice current profit for the long term" was borne by existing shareholders through dilution from repeated issuance, rather than paid by management itself. Per the report, the CEO's total 2025 compensation was about $14.467 million; although it is mostly equity incentives, four-year vesting, and IND-linked PSUs with a high at-risk proportion, from a conservative shareholder's perspective it is not cheap. The report's characterization is apt: this incentive setup "looks more like the standard configuration of a growth biotech than the style of a disciplined capital allocator."

  Filling in Baillie Gifford's implicit premise of "is it willing to sacrifice current profit for five to ten years out": on "willing to sacrifice the present and bet on the long term," Insmed is a clear yes (continuous enormous R&D investment is the proof), and per the report management is honest with sound governance (say-on-pay about 97%, no related-party transactions, internal controls deemed effective by EY). But "interests deeply tied to the company" can only get a moderate rating — the binding relies on compensation incentives under rule requirements rather than founder-style enormous ownership; more importantly, its way of achieving long-term growth includes the real cost of existing shareholders being continuously diluted. This is consistent with the report's judgment of "management and capital allocation 3/5, not bad but far from excellent": trustworthy, but not the scarce kind of capital allocator who "spends frugally and treats every dollar of shareholder capital as its own."

  Jun 11, 2026
• QIf it vanished tomorrow, how much would customers miss it? Is its growth model sustainable and not reliant on harming society or regulation?6/10

  A

  The conclusion first: if Insmed vanished tomorrow, patients would miss it enormously — because its two drugs are almost "irreplaceable" in their respective indications, its hardest single item of long-term value; at the same time, its growth model is healthy, even positive, on "social and regulatory sustainability" (treating real disease, filling a real gap, following the proper regulatory path), relying on no means that harm society or exploit regulatory loopholes. This question is a rare dimension where Insmed can score high.

  First, answer the indispensability question of "how much customers would miss it." The answer is: within the patient group it serves, the degree of longing is extremely high, almost to the point of "no substitute." BRINSUPRI is the first and only FDA-approved therapy for non-cystic fibrosis bronchiectasis — a disease recorded in the medical literature for more than two hundred years, with no approved targeted drug before it. For a bronchiectasis patient stable on the drug whose exacerbations have consequently decreased, if the drug vanished tomorrow he could not find a second equivalent option and could only fall back to the era with no disease-modifying therapy. ARIKAYCE is the same: per the report, in refractory MAC lung disease the company is not aware of any other approved dedicated inhaled therapy in North America, Europe, or Japan, and it is written into multiple ATS/ERS/ESCMID/IDSA treatment guidelines. This layering of "guideline recommendation + label exclusivity + long-term chronic-disease use" is exactly the "indispensability" Baillie Gifford values — and this longing is at the level of clinical necessity rather than brand preference, which carries more weight.

  But add an honest qualifier: the number of people who would miss it is limited. This is a rare-disease drug, and the beneficiary group is hundreds of thousands of bronchiectasis patients and ten-to-twenty thousand refractory MAC patients, rather than a tens-of-millions-scale mass public. So "indispensability" is extremely high in depth but limited in breadth — indispensable to every patient on the drug, but the "surface that would miss it" across society as a whole is narrow. In Baillie Gifford's standard, deep indispensability beats shallow breadth, and Insmed belongs to the "narrow but deep" category.

  Now the dual premise of "is the growth sustainable and not reliant on harming society or regulation," where Insmed stands firm on both sides, which is where it is truly clean.

  First, its growth essentially creates social value rather than shifting costs onto others. What it does is turn a serious chronic lung disease that was "untreatable" into "treatable" — in the Phase 3 ASPEN study BRINSUPRI reduced the annualized exacerbation rate by about 19%–21% versus placebo, and ARIKAYCE's ENCORE study 6-month culture-conversion rate was 87.8% vs 57.0%. This is growth backed by real clinical benefit, not expansion by manufacturing demand or harming consumers.

  Second, its growth path is entirely within the regulatory framework and relies on regulation rather than evading it. Every step of its revenue is built on formal approvals from agencies such as the FDA/EMA, under the hard constraints of accelerated-approval confirmatory trials and reimbursement and pricing review. The report also factually notes that the company does not shy away from these regulatory obligations (such as ARIKAYCE's accelerated-approval confirmatory trial). This means its business model is "aligned" with regulation — regulation grants it a time-limited monopoly, and it delivers with real efficacy data, a sustainable virtuous cycle rather than "quick money that regulators will shut down."

  One point that needs a balanced view is the tension between pricing and payers — but this belongs to "pressure on commercial sustainability," not "harming society." BRINSUPRI has an annual price (before discounts) of about $88,000, and as the treated population expands, scrutiny of real-world efficacy and budget impact by commercial insurance and government payers will only tighten. High-priced innovative drugs do trigger a social discussion of "affordability," but this is a common issue across the entire innovative-drug industry, and Insmed's high price corresponds to real, previously nonexistent clinical benefit rather than inflated pricing or abuse of market dominance — its pricing power "is never fully free and must be balanced against payers," which actually shows society has checks and balances and that growth will not be unrestrained.

  Overall judgment: indispensability — extremely high for its patient group (exclusivity + guidelines + chronic-disease stickiness), but with a narrow beneficiary base, a case of "narrow but deep"; social and regulatory sustainability — healthy and positive, treating real disease, filling a real gap, following proper approval, relying on no means that harm society or arbitrage regulation, with tension arising only from the industry-common issue of high-price payment. This is one of the few items in Insmed's overall profile that can be given a high score with equanimity, and it is fully consistent with the report's positioning of "high unmet need, scarce respiratory-specialty asset."

  Jun 11, 2026
• QWhat are the unit economics of this business (gross margin, incremental returns)? Does it get better or worse at scale? Where does the money it earns go?4/10

  A

  The conclusion first: Insmed's unit economics are very pretty on the surface but unproven underneath — product gross margin is as high as about 80% and still rising as the product mix optimizes, giving it strong potential for "unit economics improving at scale"; but today its incremental returns are negative, because R&D and SG&A expenses still far exceed gross profit, and the money it earns (and the money it raises) is almost entirely reinvested into R&D and commercialization expansion. It has the "structure" to become a high-unit-economics business, but has not yet gotten there.

  First, the gross-margin layer, its strongest side. In Q1 2026 product cost was only $47.4 million against total revenue of $306.0 million, a gross margin of about 84.5% — a classic feature of a quality innovative-drug business: once a drug is successfully developed, the marginal manufacturing cost of selling one more box is extremely low. More critically, the structure is optimizing: the report notes BRINSUPRI's own manufacturing cost is lower than ARIKAYCE's, and as BRINSUPRI's share of revenue rises quickly (in Q1 2026 it already accounted for about two-thirds of total revenue), the overall gross margin has structural upward momentum. But one accounting distortion must be honestly flagged: this 84.5% contains water — the report explicitly notes that inventory costs formed before BRINSUPRI's FDA approval were previously expensed to R&D and will no longer enter product cost when sold, which "flatters" gross margin in the short term, so it should not be mechanically annualized. Stripping out this timing effect, a more steady-state gross-margin measure is close to the roughly 79.7% for 2025 disclosed in the report — still very high, but not as exaggerated as 84.5%.

  Now incremental returns and the core question of "better or worse at scale." Here gross profit and true profit must be separated — high gross margin does not equal high unit economics. Today's fact is: Q1 2026 R&D expense $209.5 million, SG&A expense $247.3 million, totaling $456.8 million, 1.5 times the $306.0 million total revenue for the same period. In other words, gross profit simply cannot cover R&D plus selling expenses, leading to a Q1 2026 operating loss of $153.3 million and net loss of $163.6 million. So on the incremental-return measure of "how much you earn back per dollar invested," today it is negative.

  But on "will it get better at scale," I lean cautiously optimistic — provided the expense ratio does indeed dilute with scale. The logic: R&D spending is broadly for "the entire pipeline and future labels" and does not grow linearly with revenue; once the sales team and specialty channel are built, the marginal selling cost of serving one more patient is very low. So in theory, as long as BRINSUPRI revenue keeps expanding (management guides at least $1 billion for 2026), R&D intensity declines as the pipeline matures, and the SG&A-to-revenue ratio dilutes with scale, unit economics will turn from "negative" to "positive" and gradually rise. This is exactly the source of the "long-term owner-earnings margin reaching 20%–32%" assumption in the report's neutral/optimistic scenarios. It has this high-operating-leverage structure, which is a positive; but "will get better" is currently an inference and an assumption, not a delivered fact, and under Baillie Gifford's standard it cannot be treated as an accomplished conclusion.

  Finally, "where the money it earns goes," which bears on capital-allocation quality. The answer: the money goes mainly to two places — R&D (advancing the pipeline such as TPIP and ARIKAYCE's label expansion) and commercialization expansion (selling investment for BRINSUPRI's global ramp). This is a "reinvest for future growth" direction, itself a reasonable growth-style use of money. But add two honest qualifiers: first, because it cannot yet self-fund (operating cash flow is still negative), a substantial part of the money was raised through financing rather than earned — per the report, share count rose from about 118.7 million at the end of 2021 to about 216.5 million by the end of March 2026, with existing shareholders continuously diluted to foot the bill for these investments; second, the company currently pays no dividend and does no buybacks, putting all cash into reproduction, which is correct for a growth stock but also means shareholders get no cash return today and all returns are staked on future delivery.

  Overall judgment: the "ceiling" of unit economics is very high — 80%-level gross margin + high operating leverage + a dilutable expense-ratio structure give it the potential to become an excellent high-unit-economics business that should get better at scale; but the "floor" is that incremental returns are negative today, investment is supported by financing, and the high gross margin contains short-term water from inventory expensing. This is fully consistent with the report's judgment that "the headline gross margin looks decent, but today it is still a capital-intensive, intellectual business of high R&D + high commercialization spend, and one must look at long-term cash-generating capability."

  Jun 11, 2026
• QFor it to 5x in ten years, which conditions must hold simultaneously? Are these conditions realistic? What expectations does today's share price imply?3/10

  A

  The conclusion first: for Insmed to 5x from today's size in ten years, a long string of conditions — "multiple high-variance events succeeding at once + valuation not compressed + no further large-scale dilution" — must all hold, none missing; these conditions are not impossible, but the probability of all holding at once is not high. And today's share price (about $91.88, market cap about $19.9 billion) itself already implies fairly optimistic expectations — the market has long priced it as a company that "can grow into a highly profitable specialty platform in the future," rather than as an ordinary loss-making biotech. In other words, a large chunk of the 5x upside has already been advanced.

  First, pin down the base and the magnitude of "5x." A special note: at the time the report was written it anchored a share price of about $109.53 and a market cap of about $23.6 billion; but as of June 10, 2026, INSM's share price had fallen back to about $91.88, with a market cap of about $19.9 billion (about $94.17 on June 8, 216.75 million shares). That is, the share price has fallen about 16% since the report, and the valuation starting point is somewhat lower than at the time. On the current base of about $19.9 billion, a ten-year 5x means the market cap must reach about $100 billion — a fairly extreme target: for reference, mature, profitable peers backed by real earnings, United Therapeutics currently has a market cap of about $25 billion, 2025 net income of about $1.335 billion, and a P/E of about 20x, and Neurocrine has a market cap of about $16 billion and a P/E of about 24x. To reach a hundred-billion market cap, Insmed would broadly need to achieve several times the profit scale of these mature platforms — extremely difficult.

  To support a 5x, the following conditions must hold almost simultaneously — filling in Baillie Gifford's implicit premise of "which conditions hold at once + what today's price implies":

  First, BRINSUPRI must grow from "successful launch" into a "global blockbuster." Not just delivering the guidance of at least $1 billion for 2026, but sustaining high penetration across the U.S., Europe, and Japan, with the refill rate (persistence) and net price staying high for years — precisely the core variable the report repeatedly stresses is "not yet proven by multiple years of data."

  Second, ARIKAYCE's label expansion must be delivered smoothly. ENCORE positive, sNDA submission in the second half of 2026 is only the first step; it still needs approval and a real ramp after expanding the treatable population from refractory to the entire MAC group.

  Third, at least one key TPIP indication must succeed in Phase III and be commercialized, truly growing into a "third growth pillar" — a high-variance clinical bet whose failure the report lists as a signal that would trigger reassessment.

  Fourth, the expense ratio must decline markedly as revenue expands, turning owner earnings that are still negative today (Q1 2026 operating loss $153.3 million) positive and up to a steady-state margin on the order of 25%–30%.

  Fifth, the company must essentially stop large-scale dilution. Otherwise, even if total market cap rises, per-share value will be diluted by new shares — and its share count has nearly doubled over the past four years, a real historical burden.

  Sixth, mechanism-based competition must not break exclusivity too early or too hard. Once same-target drugs like Boehringer's verducatib (already in Phase III AIRTIVITY, about 1,200 patients) are approved and siphon off share, BRINSUPRI's share and pricing power will both come under pressure.

  Among these six, if any one or two are discounted, the 5x logic breaks. Each has a real path to holding, but "all holding simultaneously" is a low-probability product-of-events — exactly the allure of Baillie Gifford–style blue-sky imagination, and also its fragility.

  So what does today's price imply? The report's judgment is direct: the market "is not pricing INSM as an ordinary loss-making biotech, but as a company that may grow into a highly profitable specialty platform in the future," and on that basis classifies the current price as "already near the lower-to-middle part of the optimistic scenario, with insufficient margin of safety." The report's three intrinsic-value tiers are conservative $25–40, fair $45–80, and optimistic $95–130; the current roughly $91.88 already sits at "the upper end of the fair range, close to the lower end of the optimistic range." This means the price has already prepaid the optimistic script of "multiple successes probably happening," sharply compressing the pure incremental room left for a 5x — you are betting on an outcome that must be nearly perfect at a price close to "optimistic pricing," rather than betting on a possible good outcome at a "pessimistic price."

  Honest conclusion: the condition list for a ten-year 5x genuinely exists and is partly already advancing (BRINSUPRI's ramp and ENCORE's positive result are real progress), so it is not a fantasy; but this string of conditions needs to "all hold simultaneously," the product probability is not high, and the current valuation already implies high success expectations, prepaying most of the upside. To Baillie Gifford's question of "are these conditions realistic," my answer is: each one alone is possible, but together it is a "low-probability perfect script," and today's price requires you to pay close to full price for that perfect script — insufficient margin of safety, consistent with the report's conclusion of "Watch, not buy heavily now."

  Jun 11, 2026
• QWhy hasn't the market realized all this yet? Is it not understanding, looking down on it, or not seeing far enough? What would become the "narrative inflection point"?2/10

  A

  The conclusion first: for Insmed this question must be answered honestly in reverse — the market has basically "already realized" its growth, rather than not understanding it, looking down on it, or not seeing far enough. It has heavy sell-side coverage, a "strong buy" consensus, and a valuation that already fully (even excessively) prices in the optimistic script. What is truly "not yet fully priced by the market" is instead the downside risk — refill rate below expectations, mechanism-based competition arriving, further dilution. So Baillie Gifford's classic undervaluation logic of "why hasn't the market realized" does not hold for this stock; it is more like the opposite case of "the market has long been bullish and sees very far." This must be stated truthfully; one cannot force a claim of undervaluation just to fit a growth narrative.

  First, falsify the premise of "whether the market has not yet realized." The evidence is clear: as of now, analysts maintain a "strong buy" consensus on INSM, with an average target price of about $199, implying substantial upside to the current price. A stock given a target price of "double the current price" with a uniformly bullish rating is clearly not an "unnoticed, buried, dusty stock." The report's relative-valuation table corroborates this: per the report, a rough estimate on 2026 guidance puts its EV/sales at around 15x — the market uses such a multiple to price a not-yet-profitable company, whereas mature, profitable United Therapeutics is only about 20x P/E and Neurocrine about 24x P/E. The market has already priced the expectation of "growing into a highly profitable specialty platform" into the price, rather than failing to understand its potential — the report characterizes this as "the market is already pricing in a high-success-probability large pipeline, which is very dangerous."

  So do the three explanations of "not understanding / looking down / not seeing far" each apply? None of the three really applies. Not understanding: BRINSUPRI's first-in-class status, ARIKAYCE's guideline exclusivity, and ENCORE's positive readout are all public, clear, widely reported facts, with ample institutional coverage and no cognitive blind spot. Looking down: quite the opposite, the market gives it a high valuation and high target price — "overrating" it. Not seeing far: also does not hold — the current price itself is built on far-out imagination of BRINSUPRI's multi-year ramp, ARIKAYCE's expansion, and TPIP's delivery; the market has already counted in even the very-far-out good things, rather than not seeing far enough.

  So what has the market actually "not yet fully realized"? The answer is the downside factors covered by optimism. The report's counterarguments list them clearly: current true owner earnings are negative, Q1 2026 still had a net loss of $163.6 million; channels are highly concentrated (the four largest customers account for 38%/22%/16%/14% of gross product revenue); mechanism-based competition is on the way (Boehringer's verducatib in Phase III AIRTIVITY, about 1,200 patients); historical dilution is significant, with possible further dilution ahead. Within a consensus of "strong buy, target price $199," these risks are more easily suppressed by the optimistic narrative — what the market underestimates is risk rather than opportunity.

  Also add an objective side-note: since the report was written (about $109.53), the share price has fallen back to about $91.88 (June 10, 2026, down over 7% that day), with a range high once reaching $212.75 and a low of $86 — extremely volatile. This itself shows that the market's "far-out optimistic pricing" is not solid and is being violently repriced around fundamentals and sentiment; it is not a "neglected, waiting-to-be-discovered" stock, but a "fully watched, repeatedly contested at a high level" stock.

  Filling in Baillie Gifford's implicit premise of "what would become the narrative inflection point": since it is already optimistically priced, what can truly change the narrative is mostly hard events that break optimism to the downside or exceed it to the upside, rather than "the market finally discovering it." Downside inflection: BRINSUPRI revenue clearly below the "at least $1 billion annual revenue" pace for two consecutive quarters, refill rate or net price weakening, ARIKAYCE's sNDA blocked, TPIP Phase III failure, or the company issuing large amounts again — any one would puncture the optimistic script and trigger valuation compression. Upside inflection: BRINSUPRI penetration and refills continuing to beat expectations and showing an expense-ratio inflection, ARIKAYCE's label expansion approved and ramping, TPIP's key Phase III succeeding — these would firm up the "optional upside" into a "third curve," opening new imagination beyond the current optimistic pricing.

  Honest conclusion: for Insmed this question must be understood in reverse — the market has already fully, even excessively, realized its growth, rather than "not yet realized" it; its insufficient margin of safety stems precisely from this. The narrative inflection point will not be "being discovered," but specific clinical and commercial events that "confirm or falsify optimism." This is fully consistent with the report's judgment of "a good company, but the current price is not generous, rating Watch" — calling it an undervalued stock buried by the market would be dishonest.

  Jun 11, 2026